Determination of ticlopidine in human plasma by capillary gas chromatography with ion trap detection by Pena, Angelina et al.
Determination of ticlopidine in human plasma by capillary gas
chromatography with ion trap detection
Angelina Pena *, Celeste Lino, M. Irene N. Silveira
Laboratory of Bromatology, Faculty of Pharmacy, University of Coimbra, 3000 Coimbra, Portugal
Received 24 April 2002; received in revised form 20 December 2002; accepted 27 December 2002
Abstract
A gas chromatographic method for determination of ticlopidine in human plasma using mass spectrometric detection
was developed. A Perkin Elmer model 8500 gas chromatograph coupled to an ion trap detector (ITD) in electron
impact mode (EI) was used. The gas chromatograph was fitted with a 30 m/0.32 mm i.d., DB-17 capillary column
with a film thickness of 0.25 mm. The compounds were isolated from plasma by Extrelut-1 solid-phase extraction using
hexane as the solvent of elution. The detection and quantification limits for this method were 0.005 and 0.01 mg/ml,
respectively. The calibration curves were linear from 0.01 and 2.5 mg/ml. Recoveries from human plasma spiked at 0.01
and 2.0 mg/ml ranged from 84.4 and 87.3%. The coefficient of variation (CV) was between 5.1 and 6.9%. The results
show that the sensitivity, accuracy and precision of the method are adequate for the determination of ticlopidine in
human plasma samples. The ITD in SIM mode allows the unequivocal identification of ticlopidine. The suitability of
this method was evaluated in the determination of ticlopidine in plasma from healthy volunteers following oral
administration of a dose of 500 mg/day.
# 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Ticlopidine (Fig. 1), is a potent and long acting
inhibitor of platelet aggregation [1]. Platelets
contribute significantly to arterial-occlusive
thrombosis, one of the major causes of death
and disease throughout the world. Consequently,
inhibiting platelet function is a potentially impor-
tant therapeutic goal. Among agents that inhibit
platelet function, ticlopidine shows a wide spec-
trum of antiplatelet activity [2]. Ticlopidine is
superior to aspirin and dipyridamole as anti-
thrombotic agent towards different kinds of ex-
perimental thrombosis [3,4].
Studies in animals and man demonstrated that
ticlopidine is a potent inhibitor of platelet aggre-
gation induced by adenosine diphosphate and
variably inhibits aggregation due to collagen,
adrenaline (epinephrine), arachidonic acid, throm-
bin and platelet activating factor [5].
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Usually anti-thrombotic therapy is a long-term
process, and its important to monitor not only the
anti-thrombotic effect but also drug concentration
in plasma.
Three main analytical techniques are described
for the determination of unchanged ticlopidine in
plasma or urine: high-performance liquid chroma-
tography with ultraviolet detection (HPLC-UV)
[6/10], gas/liquid chromatography with nitrogen
detection (GC-NPD) [11] and gas chromatogra-
phy-mass spectrometry (GC-MS) [12,13].
High-performance liquid chromatographic
methods have been reported for ticlopidine deter-
mination in human plasma with UV detection at
230/235 nm [6,7], and at a lower wavelength
(213/215 nm), corresponding to the maximum of
absorption, and consequently to achieve a better
sensitivity [8/10].
Arnoux et al. [12] proceed to the comparison of
the three methods reported in literature for the
determination of ticlopidine in plasma: HPLC-
UV, GC-NPD and GC-MS. They observed that
GC methods are preferable to the HPLC method
evaluated. The GC-NPD method was found to be
a suitable technique but, for pharmacokinetic
studies, GC-MS was found to be the most
reproducible, sensitive and specific assay.
In addition, effective control requires appropri-
ate analytical methodology, which must provide
enough sensitivity as well as the ability to confirm
the identity of the analytes. Owing to its specifi-
city, gas chromatography coupled with mass
spectrometry detection is a powerful confirmation
technique.
Therefore, in our laboratory we have developed
a analytical method by gas chromatography
coupled with a ion trap detector (ITD) for the
determination of ticlopidine in human plasma.
For sample processing, liquid/liquid extraction
procedure using 2% isoamylic alcohol in n -hexane
[10], n-heptane/isoamyl alcohol mixture (98.5:1.5,
v/v) [6] and n -hexane [7] are described in the
literature. Methods based in solid-phase extraction
using Extrelut [12] and Bond Elut C18 columns [8]
are also reported.
In this work, blood samples were centrifuged
immediately after being collected. Solid-phase
extraction of ticlopidine from plasma was per-
formed using Extrelut-1 columns, according Ar-
noux method [12].
Ticlopidine dichloro derivative, which we used
as internal standard for quantitative determina-
tions, has been described in a number of reports
[7/9,12].
The aim of this study was to develop and
validate a GC-MS method for measuring ticlopi-
dine levels in plasma samples. After validation the
method was evaluated in samples collected from
healthy volunteers who were administered a dose
of 500 mg/day.
The analytical method described in this paper is
reproducible, sensitive and specific and allows the
routine assessment of ticlopidine plasmatic con-
centrations.
2. Experimental
2.1. Reagents and solvents
Each batch of reagents and solvents was tested
for any impurities before use. Ticlopidine-[5-(o -
chlorobenzyl)]-4,5,6,7-tetrahydrothieno-[3,2-c ]
pyridine hydrochloride and the internal standard
5-[2,4-(o -dichlorobenzyl)] 4,5,6,7,-tetrahydro-
thieno-[3,2-c ]pyridine hydrochloride (PCR 2735)
were obtained from Sanofi Recherche (Montpel-
lier, France).
Methanol and hexane Baker analysed for en-
vironmental monitoring procedures by capillary
GC were purchased from Baker (Netherlands).
Extrelut-1 columns were supplied by Merck
(Darmstadt, Germany).
Water was obtained by purifying distilled water
in a Milli-Q filtration system (Millipore, Bedford,
MA).
Individual stock standards solutions (1 mg/ml)
were prepared in methanol and stored at 4 8C for a
maximum period of 1 month. The final working
Fig. 1. Chemical structure of ticlopidine.
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standard solutions were prepared in methanol at
0.01, 0.05, 0.2, 0.5, 1.0, 2.0 and 2.5 mg/ml.
2.2. Apparatus and chromatographic conditions
A Perkin Elmer model 8500 gas chromatograph
coupled to an ITD (Finnigan Mat 800) in electron
impact mode (EI) was used. The gas chromato-
graph was fitted with a 30 m/0.32 mm i.d., DB-
17 capillary column with a film thickness of 0.25
mm (J&W Scientific). The helium flow used was 1
ml/min. The linear velocity of helium (carrier gas)
was 32 cm1 at 200 8C and a column head
pressure of 30 KPa. Injector temperature was
280 8C. Samples were injected in the splitless
mode with a 1 min purge off. The oven tempera-
ture was programmed as follows: initial tempera-
ture of 50 8C and hold for 1 min, and temperature
increase at a rate of 40 8C/min; first intermediate
temperature of 200 8C and temperature increase at
a rate of 10 8C/min; second intermediate tempera-
ture of 252 8C and temperature increase at a rate
of 40 8C/min; final temperature of 270 8C and hold
for 1 min. The injection volume used was 1 ml.
The column was directly inserted into the ITD
source. The mass spectrometric conditions were as
follows: electron energy, 70 eV; electron multiplier
voltage, 2300 V; transfer line temperature 270 8C.
The ITD was optimised with the automatic set-up
program in the AUTOMATIC GAIN CONTROL soft-
ware and produced mass spectrum that met
calibration compound (perfluorotributylamine)
performance criteria. Tune values used to set the
resolution at m /z 69, 131, 264 and 502, in the
spectrum of perfluorotributylamine, were 50, 95,
130 and 200, respectively at a ‘B’ value of 5000.
The computer system connected to the mass
spectrometer must allow continuous acquisition
and storage of all mass spectra obtained, through-
out the complete chromatographic program. Mass
spectra were normalised after background sub-
traction.
2.3. Sample preparation
Blood samples (3.0 ml), obtained from 10
healthy volunteers after administration of a dose
of 500 mg/day, were collected in heparinized glass
centrifuge tubes without anticoagulants. After
immediate centrifugation, the plasma was trans-
ferred to a 10-ml glass-stoppered tube and stored
at /30 8C until the analysis.
2.4. Extraction procedure
The samples of plasma (0.25 ml) were diluted
with 0.25 ml distilled water and were spiked with
0.5 mg of the internal standard. After vortexing (10
s) the mixture was applied to the Extrelut-1
column. The column was left standing for 20 min
and compounds were eluted with 6.5 ml of hexane
into a 10-ml glass tube. The eluant was evaporated
under a stream of nitrogen at 30 8C and the
resulting dry residue was dissolved in 0.1 ml of
hexane.
3. Results
3.1. Chromatographic analysis and detection
The usefulness of the DB-17 column is clearly
shown by the adequate resolution of the ticlopi-
dine and the internal standard in the total ion
chromatogram, produced by scanning over the
mass range m /z 200/500 amu (Fig. 2).
The presence of these compounds in samples
was confirmed by comparison of their GC reten-
tion times and ion trap mass spectra with those of
calibration standards analysed under identical
Fig. 2. Total ion chromatogram of ticlopidine and internal
standard.
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conditions and by additional library searches. Ion
trap mass spectras of ticlopidine and internal
standard ranged from 0 to 300 amu are shown in
Figs. 3 and 4.
The mass spectrum of ticlopidine is charac-
terised by a molecular ion at m /z 263 (M), and
fragments at 125 (M-C7H8NS) and 110 (M-
C8H8NCl) (Fig. 3). The mass spectrum of ticlopi-
dine dichloro derivative, used as internal standard,
is characterised by a molecular ion at m/z 297
(M), and fragments at 159 (M-C7H8NS) and 110
(M-C8H8NCl). The ions m /z 110, 125, 263
and 110, 159, 297 were monitored for quantifica-
tion of ticlopidine and internal standard, respec-
tively.
3.2. Quantification
A constant amount of the internal standard
was added to calibration standards just
before injection. The peak measurements
used were based on the extracted ion
current profiles for the specific characteristic ions
of each calibration standard and internal
standard.
3.3. Determination in real samples
The suitability of the method validated was
evaluated in plasma samples collected
from healthy volunteers following oral
administration of a 500 mg/day dose. Blood
samples were collected after 1.0, 2.0, 3.0, 4.0, 5.0
and 6.0 h after the administration of ticlopidine
dose.
3.4. Validation results
The limits of detection (LODs) and quantifica-
tion (LOQs) were estimated in accordance to the
base line noise, considering a signal-to-noise ratio
of 3:1 and 10:1, respectively. The values obtained
for this method, calculated by spiking sample
Fig. 3. Mass spectra of ticlopidine.
Fig. 4. Mass spectra of internal standard.
Table 1
Assay linearity for ticlopidine
r -Value Slope9/S.D. Intercept9/S.D.
Intra-day precision 0.9994 5.87/1039/0.30/103 0.0839/0.105
(n/5) R.S.D./0.09% R.S.D./5.8%
Inter-day precision 0.9990 6.39/1039/0.78/103 /0.0579/0.142
(n/5) R.S.D./0.16% R.S.D./9.6%
R.S.D., relative standard deviation.
A. Pena et al. / J. Pharm. Biomed. Anal. 32 (2003) 879/885882
extracts of bank plasma, were 0.005 mg/ml for
LOD and 0.01 mg/ml for LOQ.
The calibration graphs for the standard of
ticlopidine was obtained by plotting the ratio of
the peak areas of the ticlopidine standard and the
internal standard, against their concentration ratio
between 0.01 and 2.5 mg/ml, i.e. at 0.01, 0.05, 0.2,
0.5, 1.0, 2.0 and 2.5 mg/ml, respectively.
Peak area of ticlopidine over the I.S. varied
linearly with concentration over the range used.
Intra-assay precision was determined for calibra-
tion curves prepared the same day in replicate, and
inter-assay precision was determined for calibra-
tion curves prepared on different days. Results are
given in Table 1. For each point of calibration
standards, the concentrations were back-calcu-
lated from the equation of the linear regression
curves and the R.S.D.s determined. The linearity
of the method was confirmed by comparing the
slopes and the intercepts of linear calibration
curves with zero, and the correlation coefficients
with 1.
No significantly interfering peaks from the
matrix were observed at the retention times of
both ticlopidine and internal standard, as we can
observed in the total ion chromatogram of the
blank assay (Fig. 5).
The accuracy and within-day and the between-
day precision of the present method were determi-
nate by performing extraction batches of samples
of blank plasma, at two fortification levels, 0.01
and 2.5 mg/l and one blank (to check for inter-
ference), in duplicate for 3 days.
4. Discussion
The solid-phase extraction was chosen because
of its efficiency and the relative speed compared
with conventional liquid/liquid extraction. It was
performed using Extrelut-1 columns, according
Arnoux et al. method [12]. Moreover, these
columns compared with reversed-phase liquid/
solid extraction columns no conditioning or wash-
ing is necessary.
Although Ro´na et al. [8] reported lower recovery
than the obtained by Arnoux et al. [12], our results
are similar to Arnoux values. The formers have
used a Bond Elut C18 solid-phase extraction for
the isolation of the compounds from plasma.
Comparing the three methods (HPLC-UV, GC-
NPD and GC-MS) reported for the determination
of ticlopidine from human serum, Arnoux et al.
[12] found that HPLC reproducibility was accep-
table down to 0.05 mg/ml and the limit of
quantification was again 0.05 mg/ml. On the
contrary, Furlan et al. [10] state that for the
HPLC method developed in their laboratory, the
limit of reproducible and accurately quantifiable
sensitivity is 0.02 mg/ml, whereas the lowest
detectable concentration is 0.01 mg/ml, and hence
comparable with determination levels reported by
GC-NPD [11,12].
The limit of quantification of the HPLC method
optimised by Bo et al. [6], proved to be as low as
0.005 mg/ml with values of precision of 8.51%.
Although these values are comparable with the
values obtained with GC-MS, it lacks specificity, it
do not allow the confirmation of identity of the
compounds. Using HPLC, problems of specificity
were observed by Arnoux et al. [12], since en-
dogenous compounds were found to alter repro-
ducibility.
The reported GC-MS method [12] uses a quad-
ruple detector whereas in our laboratory we have
used an ITD.
In the EC guidelines the monitoring of three
ions, the molecular ion and two structurally
significant fragment ions, is advised [14]. The
presence of the analytes was determined by the
presence of the three selected ions, the molecular
and two fragment ions at the correct retention time
and with the correct abundance ratio [14]. The
Fig. 5. Total ion chromatogram of extract of bank plasma.
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retention times for ticlopidine and internal stan-
dard were 11.9 and 13.7, respectively.
Ticlopidine yield molecular ion at m /z 263 and
two fragment ions, at m /z 110 and 125, that were
monitored, and permit it easy identification.
Therefore, the limit of quantification obtained by
our experimental conditions was slightly higher
compared with the mass spectrometric method
proposed by Arnoux et al. [12] where only the
molecular ion was monitored. At low concentra-
tions the monitoring of three ions could be
insufficient due the influence of co-extracted
matrix components and in case of doubt a full
scan identification was also performed.
Low background interferences in human serum
easily permitted the limit of detection achieved
0.005 mg/ml.
During the development of the method, the
internal standard, ticlopidine dichloro derivative
was essential for accurate quantification of ticlo-
pidine in biological samples.
Experiments with spiked human serum samples
showed that mean recoveries ranged from 84.4 to
87.3% at fortification levels, 0.01 and 2.0 mg/ml.
Table 2
Inter and intra-assay validation results of ticlopidine from human serum
Fortification level (mg/ml) Number assay (n ) Recovery variation (%) Recovery mean (%) %CV intra-day %CV inter-day
0.01 6 82.9/87.5 84.4 6.9 8.6
0.2 6 86.1/91.0 87.3 5.1 7.3
CV, coefficient of variation.
Fig. 6. Mean plasma concentration of ticlopidine after single 500-mg oral dose.
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The absolute recovery values were high and the
concentration dependence of recovery was negli-
gible, as we can observe in Table 2. Within and
between-day precision CV% values, obtained by
analysing duplicate batches during 3 days, were
lower than 10%, ranging between 5.1 and 8.6%
(Table 2). The results of linearity, accuracy and
precision obtained assess the performance of the
proposed method.
The method was applied to healthy volunteers in
order to evaluate its application to routine assess-
ment of ticlopidine plasma concentrations in
pharmacokinetic studies following therapeutic
doses in human subjects.
Mean plasma concentrations of ticlopidine of 10
healthy volunteers, measured by GC with ion trap
detection fell from 0.59 mg/l at 2 h to 0.10 mg/l at 6
h post-dose, following a 500 mg/day dose (Fig. 6).
The time taken to achieve the maximal
plasma concentration was approximately 2 h
and it is in agreement with others studies
[13,15,16].
All the validated parameters, accuracy, sensitiv-
ity and precision, were within the necessary limits.
Therefore, the developed analytical method was
found to be suitable for the determination of
ticlopidine plasmatic concentrations in healthy
volunteers.
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